UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MAY 2026

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant's name into English)

An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On May 5, 2026, BioNTech SE (the "Company") issued a press release announcing its first quarter 2026 financial results and corporate update and details of a conference call to be held at 8:00 am EDT on May 5, 2026 to discuss the results. The press release and the conference call presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein.

The information contained in Exhibits 99.1 and 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By: /s/ Ramón Zapata-Gomez
Name: Ramón Zapata-Gomez
Title: Chief Financial Officer

By: /s/ Dr. Sierk Poetting
Name: Dr. Sierk Poetting
Title: Chief Operating Officer

Date: May 5, 2026

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
99.2	First Quarter 2026: Corporate Update and Financial Results

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

- ***Five additional pivotal trials for pumitamig initiated during 2026*** *in collaboration with Bristol Myers Squibb*
- ***Oncology pipeline strength and combination strategy highlighted*** *through multiple clinical data updates, including pumitamig, gotistobart and antibody-drug conjugate programs*
- ***Catalyst-rich year ahead with six late-stage pipeline data readouts expected*** *across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapies*
- ***COVID-19 2026/2027 season variant-adapted vaccine*** *development and commercial preparation underway*
- ***Operational efficiency to be enhanced through manufacturing footprint consolidation****, supporting strategic capital allocation to further advance its growing oncology pipeline toward commercialization*
- ***First quarter 2026 revenues of €118.1 million***[1]*, net loss of €531.9 million (adjusted*[2] *net loss of €494.6 million), with diluted loss per share of €2.10 ($2.46*[3]*) (adjusted*[2] *diluted loss per share of €1.95 ($2.28*[3]*))*
- ***Reaffirmed full year 2026 financial guidance and strong financial position*** *continue to de-risk execution with cash, cash equivalents and security investments of €16.8 billion*[4]
- ***Share repurchase program*** *of up to $1.0 billion over twelve months planned*

Conference call and webcast scheduled for May 5, 2026, at 8:00 a.m. ET (2:00 p.m. CET)

MAINZ, Germany, May 5, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today reported financial results for the three months ended March 31, 2026 and provided an update on its corporate progress.

"In the first quarter, we made substantial progress in executing towards our oncology strategy, highlighted by data presentations from our priority pan-tumor program pumitamig as well as our versatile antibody-drug conjugate portfolio. Simultaneously, we continue to broaden our clinical programs to include novel-novel combinations in order to inform the optimal set-up for registrational combination trials and maximize the potential of our pipeline," said **Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech**. "We will continue to focus on accelerating our key strategic programs as we remain steadfast in our vision to translate our science into survival for patients living with cancer."

Financial Review for First Quarter 2026

in millions €, except per share data	First Quarter 2026		First Quarter 2025	
	IFRS Results	Adjusted Results[2]	IFRS Results	Adjusted Results[2]
Revenues	118.1	118.1	182.8	182.8
Net loss	(531.9)	(494.6)	(415.8)	(430.8)
Diluted loss per share	(2.10)	(1.95)	(1.73)	(1.79)

Revenues for the first quarter of 2026 were €118.1 million, compared to €182.8 million for the comparative prior year period. The decrease was primarily driven by lower revenues of BioNTech's COVID-19 vaccines.

Research and development ("R&D") expenses were €557.0 million for the first quarter of 2026, compared to €525.6 million for the comparative prior year period. R&D expenses were mainly driven by higher expenses for the development of immuno-oncology ("IO") and antibody-drug conjugate

("ADC") programs, in particular pumitamig and gotistobart, as well as costs from operations of entities acquired during 2025, BioNTech China (previously Biotheus) and CureVac, and an impairment of an intangible asset. These effects were partly offset by lower R&D expenses related to the Company's COVID-19 vaccine collaboration with Pfizer Inc. ("Pfizer").

Adjusted R&D expenses were €527.1 million for the first quarter of 2026, compared to €525.6 million for the comparative prior year period. For the first quarter of 2026, adjusted R&D expenses exclude the impairment of an intangible asset.

Sales, general and administrative ("SG&A") expenses[5] were €150.8 million for the first quarter of 2026, compared to €120.6 million for the comparative prior year period. The increase was mainly driven by the ongoing commercial build-up and the inclusion of operations of entities acquired in 2025, BioNTech China (previously Biotheus) and CureVac. These costs were partly offset by a reduction in external services.

Net loss was €531.9 million for the first quarter of 2026, compared to a net loss of €415.8 million for the comparative prior year period.

Adjusted net loss was €494.6 million for the first quarter of 2026, compared to an adjusted net loss of €430.8 million for the comparative prior year period.

Diluted loss per share was €2.10 for the first quarter of 2026, compared to a diluted loss per share of €1.73 for the comparative prior year period.

Adjusted diluted loss per share was €1.95 for the first quarter of 2026, compared to adjusted diluted loss per share of €1.79 for the comparative prior year period.

Cash, cash equivalents and security investments as of March 31, 2026, were €16,763.3 million, comprising €9,939.4 million in cash and cash equivalents, €4,696.9 million in current security investments disclosed as financial assets and €2,127.0 million in non-current security investments disclosed as financial assets.

Shares outstanding as of March 31, 2026, were 252,884,261, excluding 6,143,226 shares held in treasury.

"Our revenues for the first quarter reflect the seasonal demand for COVID-19 vaccines and are in line with our expectations," **said Ramón Zapata, Chief Financial Officer at BioNTech**. "We are committed to a diligent capital allocation strategy that empowers us to pursue our goal of evolving into a leading biopharmaceutical company with multiple oncology products by 2030."

Reaffirmed 2026 Financial Year Guidance[6]**:**

Revenues for the 2026 financial year	**€2,000 – €2,300 m**

In 2026, BioNTech anticipates lower COVID-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets. The United States continues to be a competitive and dynamic market, where, as a result, lower revenues are expected. In Europe, the Company expects lower revenues as it defends its market share and begins managing the transition away from multi-year contracts. In Germany specifically, BioNTech recognizes direct sales of its COVID-19 vaccines as revenue. Hence, the anticipated declines in sales of COVID-19 vaccines in Germany will have a direct impact on the Company's topline, whereas revenues outside of Germany only affect the Company's topline as part of the 50% gross profit split with its partner Pfizer. Per the outlined partnership terms, revenues from the collaboration with Bristol Myers Squibb Company ("BMS") in 2026 are expected to be broadly in line with 2025. Revenues from the pandemic

preparedness contract with the German government and service businesses are expected to remain stable.

Planned 2026 Financial Year Adjusted Expenses[6]:

Adjusted R&D expenses	**€2,200 – €2,500 m**
Adjusted SG&A expenses[5]	**€700 – €800 m**

BioNTech will continue to focus investments on R&D and scaling the business for late-stage development and commercial readiness in oncology, while remaining cost-disciplined. Strategic capital allocation will continue to foster innovation and be a key driver of the Company's trajectory. As part of BioNTech's strategy, the Company may continue to evaluate appropriate corporate development opportunities with the aim of driving sustainable long-term growth and creating future value.

Planned Capital Return to Shareholders

The Management Board and Supervisory Board expect to authorize a share repurchase program of BioNTech's American Depositary Shares ("ADSs"), pursuant to which the Company may repurchase ADSs in the amount of up to $1.0 billion over the next twelve months. BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The program is designed to enhance capital efficiency and support long-term value creation to execute BioNTech's objective to become a multi-product company by 2030.

Manufacturing Footprint Consolidation

BioNTech continues to allocate capital strategically while optimizing capacities broadly to drive operational efficiency and sustainable value creation. To this end, BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech's partners' manufacturing capacities and completion of contracts.

BioNTech plans to exit operations at the manufacturing sites in Idar-Oberstein, Marburg, and Singapore as well as CureVac's sites, affecting up to approximately 1,860 positions in total. The exit from the sites in Idar-Oberstein, Marburg, and Tübingen is planned by the end of 2027, while operations in Singapore are expected to conclude in Q1 2027. For each of these manufacturing sites, BioNTech is exploring divestment options, including a partial or total sale.

BioNTech expects cost savings to ramp up over time, potentially reaching approximately €500 million in recurring annual savings upon full implementation of the measures in 2029.[7] These savings are intended to support the Company's capital allocation to further advance its growing oncology pipeline toward commercialization.

BioNTech continues to ensure a robust drug supply via its established manufacturing network. No impact on commercial or clinical supply nor contractual obligations is expected as the affected sites will become underutilized or idle in the next 24 months.

The full interim unaudited condensed consolidated financial statements can be found in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed today with the United States Securities and Exchange Commission ("SEC") and available at www.sec.gov.

Endnotes

[1] All numbers in this press release have been rounded.

[2] In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures

used internally as a supplemental measure of the Company's business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found at the end of this press release and in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside the Company's financial statements prepared in accordance with IFRS Accounting Standards.

[3] Calculated applying the average foreign exchange rate for the three months ended March 31, 2026, as published by the German Central Bank (Deutsche Bundesbank).

[4] As of March 31, 2026.

[5] Sales, general and administrative expenses ("SG&A") include sales and marketing expenses as well as general and administrative expenses. Adjusted SG&A expenses include adjusted sales and marketing expenses as well as adjusted general and administrative expenses.

[6] Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions ("M&A") transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov.

[7] Expected savings relative to BioNTech's 2025 cost base and CureVac's 2026 budget; do not reflect partially offsetting costs for Contract Development and Manufacturing Organizations ("CDMO") use or transfer to other sites; and exclude exit costs, which will be recorded as incurred.

[8] An overview of abbreviations of target structures and indications is compiled in a directory at the end of this press release.

Select Oncology Pipeline Updates

Next-Generation Immunomodulators and Combinations

Pumitamig (BNT327/BMS986545) is an investigational bispecific immunomodulator combining PD-L1[8] checkpoint inhibition with VEGF-A neutralization that is being developed in collaboration with BMS.

- In the first quarter of 2026, the following pivotal trials evaluating pumitamig were initiated:
  - A global Phase 3 clinical trial in patients with first-line triple-negative breast cancer ("TNBC") (ROSETTA Breast-01; NCT07173751).
  - A global Phase 2/3 clinical trial in first-line microsatellite stable colorectal cancer ("MSS-CRC") (ROSETTA CRC-203; NCT07221357).
  - A global Phase 2/3 clinical trial in first-line gastric cancer (ROSETTA Gastric-204; NCT07221149).
  - A global Phase 3 clinical trial (ROSETTA Lung-201; NCT07361497) is being conducted to evaluate pumitamig compared to durvalumab following concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer ("NSCLC").
  - A global Phase 3 clinical trial (ROSETTA Lung-202; NCT07361510) is being conducted to evaluate pumitamig compared to pembrolizumab as a first-line treatment for patients with advanced PD-L1 ≥ 50% NSCLC.

- A global Phase 2/3 clinical trial (ROSETTA Lung-02; NCT06712316) is ongoing to evaluate pumitamig in combination with chemotherapy compared to pembrolizumab and chemotherapy in patients with first-line NSCLC. The Phase 3 part of the trial is currently recruiting. Data from the Phase 2 part of the trial are expected at the American Society of Clinical Oncology ("ASCO") Annual Meeting 2026 (May 29 - June 2, 2026).

- Pumitamig is also being evaluated in additional solid tumor indications, including first-line hepatocellular carcinoma (“HCC”), second-line glioblastoma (“GBM”), first-line pancreatic ductal adenocarcinoma (“PDAC”) and first-line renal cell carcinoma (“RCC”) in various Phase 1/2 and Phase 2 trials, both as monotherapy and in combination with standard of care.

- BioNTech has several signal-seeking clinical trials ongoing evaluating pumitamig with the Company’s proprietary assets. These trials will inform the dose selection for pumitamig and explore anti-tumor activity in multiple tumors for later-stage development. Multiple data readouts from these combinations are expected in 2026.

- In April 2026, BioNTech and Boehringer Ingelheim announced a clinical trial collaboration to assess the safety, tolerability and early clinical activity of pumitamig in combination with obrixtamig (BI 764532), Boehringer Ingelheim’s investigational DLL3/CD3 T-cell engager, in extensive-stage small cell lung cancer (“ES-SCLC”). Under the agreement, BioNTech will supply pumitamig and Boehringer Ingelheim will be the regulatory sponsor of the Phase 1b/2 trial.

Gotistobart (BNT316/ONC-392) is a tumor microenvironment-selective regulatory T cell depletion candidate that targets CTLA-4 and is being developed in collaboration with OncoC4, Inc. (“OncoC4”).

- A global Phase 3 clinical trial (PRESERVE-003; NCT05671510) is ongoing to evaluate the efficacy and safety of gotistobart as monotherapy in patients with metastatic squamous NSCLC that progressed under previous platinum-based chemotherapy and PD-(L)1-inhibitor treatment.
- In March 2026, updated data from the non-pivotal dose-confirmation stage, the first of two stages of the global Phase 3 clinical trial, were presented at the European Lung Cancer Congress (“ELCC”). Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard of care chemotherapy and a manageable safety profile in patients with squamous NSCLC whose disease had progressed following anti-PD-(L)1 therapy and platinum-based chemotherapy.
- Based on current event accrual projections, interim data from the pivotal stage of the two-stage Phase 3 clinical trial are expected in 2026.
- In January 2026, gotistobart received Orphan Drug Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of squamous NSCLC. In 2022, gotistobart received Fast Track Designation from the FDA for the treatment of patients with metastatic NSCLC whose disease progressed on prior anti-PD-(L)1 therapy.

Antibody-Drug Conjugates

Trastuzumab pamirtecan (BNT323/DB-1303) is an ADC candidate targeting HER2 that is being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”).

- A Phase 1/2 clinical trial (NCT05150691) is being conducted to evaluate trastuzumab pamirtecan in patients with advanced HER2-expressing tumors. A potentially registrational cohort with HER2-expressing (IHC3+, 2+, 1+ or ISH-positive) patients with recurrent endometrial cancer (“EC”) is fully recruited.
- In April 2026, updated data from this trial were presented at the Society of Gynecologic Oncology (“SGO”) Annual Meeting. Trastuzumab pamirtecan demonstrated encouraging clinical efficacy across all HER2 expression levels and regardless of prior immunotherapy treatment. The safety profile in patients with pretreated advanced or metastatic EC was manageable and generally consistent with that of HER2-targeted biologics.
- BioNTech and DualityBio plan to file a biologics license application (“BLA”) in 2026, subject to regulatory feedback.

- A Phase 3 trial (FERN-EC-01, NCT06340568) is being conducted to evaluate trastuzumab pamirtecan compared to investigator's choice of chemotherapy in patients with advanced and HER2-expessing recurrent EC.
- A global Phase 3 clinical trial (DYNASTY-Breast02, NCT06018337) to evaluate trastuzumab pamirtecan in patients with HR-positive, HER2-low metastatic breast cancer is ongoing. Based on current event accrual projections, data are expected in 2026.

BNT324/DB-1311 is an ADC candidate targeting B7H3 that is being developed in collaboration with DualityBio.

- In February 2026, updated data from a Phase 1/2 clinical trial (NCT05914116) were presented at the ASCO Genitourinary Cancers Symposium. BNT324/DB-1311 demonstrated durable efficacy in heavily pretreated metastatic castration-resistant prostate cancer ("mCRPC") patients with no new safety signals reported.
- In April 2026, updated data from this trial were presented at the SGO Annual Meeting. BNT324/DB-1311 showed encouraging efficacy in previously treated cervical cancer and platinum resistant ovarian cancer ("PROC") particularly in patients with treatment-naïve cervical cancer. The safety profile in gynecologic malignancies was consistent with previous reports, and no new safety signals were observed.
- A Phase 3 clinical trial (NCT07365995) to evaluate BNT324/DB-1311 compared to docetaxel in patients with mCRPC, is expected to initiate in 2026.

Corporate and Commercial Update for the First Quarter 2026 and Post Period Events

- BioNTech and Pfizer developed, manufactured and delivered their variant-adapted COVID-19 vaccines, which have received multiple regulatory approvals, including full approvals, authorizations for emergency or temporary use or marketing authorizations, in more than 40 countries and regions. BioNTech is now focused on preparing for variant strain vaccine adaptation to be ready for commercial launch ahead of the upcoming 2026/2027 vaccination season, pending approvals.

- In March 2026, BioNTech announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Özlem Türeci, M.D. The new company with distinct resources, operations and funding options will advance next-generation mRNA innovations. BioNTech plans to contribute related rights and mRNA technologies to the new company to enable and support the prioritized development of next-generation mRNA innovations with disruptive potential. With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike. Ugur Sahin and Özlem Türeci will transition into the management of their new company by the end of 2026 after their current service agreements end. BioNTech's Supervisory Board has initiated an executive search to identify successors for the positions to ensure a smooth transition and seamless execution of BioNTech's strategy.

- In March 2026, BioNTech published its Sustainability Report 2025. BioNTech recognizes the responsibility it has in how it is conducting its business and the impact its activities have on the economy, people, and the environment. The Sustainability Report 2025 outlines BioNTech's efforts, progress, key initiatives, and data as well as highlights in its corporate sustainability and responsibility over the past year.

Upcoming Investor and Analyst Events
- BioNTech Annual General Meeting: May 15, 2026
- BioNTech Second Quarter 2026 Financial Results and Corporate Update: August 4, 2026

Conference Call and Webcast Information
BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, May 5, 2026, at 8:00 a.m. ET (2:00 p.m. CET) to report its financial results and provide a corporate update for the first quarter of 2026.

To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN number will be provided.

The slide presentation and audio of the webcast will be available via this link.

Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page of the Investor section of the Company's website at www.BioNTech.com. A replay of the webcast will be made available shortly after the closing of the call and archived on the Company's website for 30 days following the call.

About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech's leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; the terms of the preliminary discussions between BioNTech and the co-founders regarding the potential contribution of certain BioNTech assets to an independent company; BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or clinical trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech's expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational clinical trials, and the registrational potential of any clinical trial BioNTech may initiate; BioNTech's expectations regarding the impact of changes to its manufacturing operations; discussions with regulatory agencies; BioNTech's expectations with respect to intellectual property; the impact of BioNTech's collaboration and licensing agreements, including BioNTech's

partnership with Bristol Myers Squibb; BioNTech's expectations with respect to developments in law, public policy, and international trade; BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech's expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech's current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or annual booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech's other product candidates; the timing of and BioNTech's ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and market its product candidates, if approved; BioNTech's ability to manage its development and related expenses; regulatory and political developments; BioNTech's ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Report on Form 6-K for the period ended March 31, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

CONTACTS

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

Media Relations
Jasmina Alatovic
Media@biontech.de

Abbreviation Overview

1L	First line
2L	Second line
ADC	Antibody-drug conjugate
B7H3	Also known as CD276, cluster of differentiation 276
BLA	Biologics license application
CTLA-4	Cytotoxic T-lymphocyte-associated protein
EC	Endometrial cancer
ES-SCLC	Extensive-stage small cell lung cancer
GBM	Glioblastoma
HCC	Hepatocellular carcinoma
HER2 (or HER3)	Human epidermal growth factor receptor 2 (or 3)
HPV16	Human papilloma virus 16
HR	Hormone receptor
IHC3+, 2+, 1+	Immunohistochemistry score 1+ (or 2+ or 3+)
IO	Immuno-oncology
ISH-positive	*In-situ* hybridization positive
mCRPC	Metastatic castration-resistant prostate cancer
MSS-CRC	Microsatellite stable colorectal cancer
NSCLC	Non-small cell lung cancer
PDAC	Pancreatic ductal adenocarcinoma
PD-(L)1	Programmed cell death protein (death-ligand) 1
PROC	Platinum resistant ovarian cancer
RCC	Renal cell carcinoma
SCLC	Small cell lung cancer
TNBC	Triple-negative breast cancer
TROP2	Trophoblast cell-surface antigen 2
VEGF-A	Vascular endothelial growth factor A

Interim Condensed Consolidated Statements of Profit or Loss

	Three months ended March 31,	
	2026	2025
(in millions €, except per share data)	*(unaudited)*	*(unaudited)*
Revenues	118.1	182.8
Cost of sales	(71.4)	(83.8)
Research and development expenses	(557.0)	(525.6)
Sales and marketing expenses	(27.9)	(13.7)
General and administrative expenses	(122.9)	(106.9)
Other operating expenses	(46.8)	(48.5)
Other operating income	30.4	61.6
Operating loss	**(677.5)**	**(534.1)**
Finance income	120.6	122.6
Finance expenses	(11.2)	(33.9)
Loss before tax	**(568.1)**	**(445.4)**
Income taxes	36.2	29.6
Net loss	**(531.9)**	**(415.8)**
Loss per share		
Basic and diluted loss per share	(2.10)	(1.73)

Interim Condensed Consolidated Statements of Profit or Loss
(Adjusted Results)

Adjusted Results (non-IFRS measures)[1]	Three months ended March 31,	
	2026	2025
(in millions €, except per share data)	*(unaudited)*	*(unaudited)*
Adjusted research and development expenses	(527.1)	(525.6)
Adjusted other operating expenses	(39.4)	(48.5)
Adjusted other operating income	30.4	46.6
Adjusted operating loss	**(640.2)**	**(549.1)**
Adjusted loss before tax	**(530.8)**	**(460.4)**
Adjusted net loss[2]	**(494.6)**	**(430.8)**
Adjusted loss per share		
Adjusted basic and diluted loss per share	(1.95)	(1.79)

[1] Certain adjusted results presented in this table are identical to BioNTech's results under IFRS Accounting Standards. Reconciliation of all other adjusted results to the Company's IFRS results can be found at the end of this press release and in BioNTech's Report on Form 6-K for the period ended March 31, 2026 filed on May 5, 2026, which is available at www.sec.gov.
[2] Tax effects are not considered as part of our non-IFRS adjustments.

Interim Condensed Consolidated Statements of Financial Position

(in millions €)	March 31 2026 *(unaudited)*	December 31, 2025
Assets		
Non-current assets		
Goodwill	370.5	367.9
Other intangible assets	1,546.8	1,606.0
Property, plant and equipment	1,112.7	1,080.9
Right-of-use assets	205.5	210.2
Contract assets	—	2.0
Other financial assets	2,279.9	2,554.2
Other non-financial assets	12.2	7.3
Deferred tax assets	14.7	13.5
Total non-current assets	**5,542.3**	**5,842.0**
Current assets		
Inventories	103.8	110.7
Trade and other receivables	539.2	924.2
Contract assets	8.9	8.1
Other financial assets	4,699.8	7,201.8
Other non-financial assets	176.6	173.8
Income tax assets	64.1	52.6
Cash and cash equivalents	9,939.4	7,675.4
Total current assets	**15,531.8**	**16,146.6**
Total assets	**21,074.1**	**21,988.6**
Equity and liabilities		
Equity		
Share capital	259.0	259.0
Capital reserve	2,468.2	2,473.3
Treasury shares	(6.1)	(7.7)
Retained earnings	17,430.0	17,961.9
Other reserves	(1,453.3)	(1,462.3)
Total equity	**18,697.8**	**19,224.2**
Non-current liabilities		
Lease liabilities, loans and borrowings	246.1	215.2
Other financial liabilities	92.0	94.9
Provisions	23.8	35.5
Contract liabilities	87.7	88.0
Other non-financial liabilities	108.8	104.2
Deferred tax liabilities	52.9	84.3
Total non-current liabilities	**611.3**	**622.1**
Current liabilities		
Lease liabilities, loans and borrowings	56.7	52.2
Trade payables and other payables	468.8	534.9
Other financial liabilities	77.5	351.7
Income tax liabilities	38.1	65.6
Provisions	167.0	145.3
Contract liabilities	758.5	754.9
Other non-financial liabilities	198.4	237.7
Total current liabilities	**1,765.0**	**2,142.3**
Total liabilities	**2,376.3**	**2,764.4**
Total equity and liabilities	**21,074.1**	**21,988.6**

Interim Condensed Consolidated Statements of Cash Flows

	Three months ended March 31,	
	2026	2025
(in millions €)	*(unaudited)*	*(unaudited)*
Operating activities		
Net loss	(531.9)	(415.8)
Income taxes	(36.2)	(29.6)
Loss before tax	**(568.1)**	**(445.4)**
Adjustments to reconcile loss before tax to net cash flows:		
Depreciation, amortization and impairment of property, plant, equipment, intangible assets and right-of-use assets	121.3	42.8
Share-based payment expenses	22.8	22.1
Net foreign exchange differences	0.4	48.3
Gain on disposal of property, plant and equipment	(0.1)	(0.1)
Finance income excluding foreign exchange differences	(111.0)	(122.6)
Finance expense excluding foreign exchange differences	11.2	7.9
Government and similar grants	(17.6)	(14.5)
Other non-cash income	—	(15.0)
Working capital adjustments:		
Decrease in trade and other receivables, contract assets and other assets	431.1	520.7
Decrease in inventories	7.0	33.8
Decrease in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions	(371.9)	(981.6)
Interest received and realized gains from cash and cash equivalents	86.6	118.6
Interest paid and realized losses from cash and cash equivalents	(3.3)	(3.1)
Income tax paid, net	(41.6)	(12.2)
Share-based payments	(2.1)	(3.6)
Government and similar grants received	14.3	23.2
Net cash flows used in operating activities	**(421.0)**	**(780.7)**
Investing activities		
Purchase of property, plant and equipment	(56.8)	(48.9)
Proceeds from sale of property, plant and equipment	1.6	0.5
Purchase of intangible assets	(22.1)	(569.2)
Acquisition of subsidiaries and businesses, net of cash acquired	—	(78.5)
Investment in other financial assets	(1,550.2)	(2,507.7)
Proceeds from maturity of other financial assets	4,278.1	4,450.6
Net cash flows from investing activities	**2,650.6**	**1,246.8**
Financing activities		
Proceeds from loans and borrowings	38.4	—
Repayment of loans and borrowings	(0.1)	(4.5)
Payments related to lease liabilities	(11.9)	(9.3)
Net cash flows from / (used in) financing activities	**26.4**	**(13.8)**
Net increase in cash and cash equivalents	2,256.0	452.3
Change in cash and cash equivalents resulting from exchange rate differences	(3.4)	(16.1)
Change in cash and cash equivalents resulting from other valuation effects	11.4	(13.2)
Cash and cash equivalents at the beginning of the period	7,675.4	9,761.9
Cash and cash equivalents as of March 31	**9,939.4**	**10,184.9**

Certain prior period lines were aggregated to conform to current period presentation.

Non-IFRS Reconciliation

Non-IFRS Reconciliation for the three months ended March 31, 2026

(in millions €, except per share data)	IFRS Results *(unaudited)*	non-IFRS adjustments (unaudited): Expenses and income from legal proceedings	Impairment and reversal	Employee-related expenses from restructuring	Income from bargain purchase and income and expenses from divestiture related items	Adjusted Results *(unaudited)*
Research and development expenses	(557.0)	—	29.9	—	—	(527.1)
Other operating expenses	(46.8)	—	—	7.4	—	(39.4)
Operating loss	**(677.5)**	**—**	**29.9**	**7.4**	**—**	**(640.2)**
Loss before tax	**(568.1)**	**—**	**29.9**	**7.4**	**—**	**(530.8)**
Net loss[1]	**(531.9)**	**—**	**29.9**	**7.4**	**—**	**(494.6)**
Loss per share						
Basic and diluted loss per share	(2.10)					(1.95)

[1] Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

Non-IFRS Reconciliation for the three months ended March 31, 2025

(in millions €, except per share data)	IFRS Results *(unaudited)*	non-IFRS adjustments (unaudited): Expenses and income from legal proceedings	Impairment and reversal	Employee-related expenses from restructuring	Income from bargain purchase and income and expenses from divestiture related items	Adjusted Results *(unaudited)*
Other operating income	61.6	—	—	—	(15.0)	46.6
Operating loss	**(534.1)**	**—**	**—**	**—**	**(15.0)**	**(549.1)**
Loss before tax	**(445.4)**	**—**	**—**	**—**	**(15.0)**	**(460.4)**
Net loss[1]	**(415.8)**	**—**	**—**	**—**	**(15.0)**	**(430.8)**
Loss per share						
Basic and diluted loss per share	(1.73)					(1.79)

[1] Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

Exhibit 99.2

First Quarter 2026
Financial Results & Corporate Update

May 5, 2026



BIONTECH

This Slide Presentation Includes Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech's expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; BioNTech's expectations regarding the impact of changes to its manufacturing operations; discussions with regulatory agencies; BioNTech's expectations with respect to intellectual property; the impact of BioNTech's collaboration and licensing agreements, including BioNTech's partnership with BMS; BioNTech's expectations with respect to developments in law, public policy, and international trade; BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech's expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this presentation are based on BioNTech's current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this presentation, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech's other product candidates; the timing of and BioNTech's ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and market its product candidates, if approved; BioNTech's ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech's ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise.

Furthermore, certain statements contained in this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and BioNTech's own internal estimates and research. While BioNTech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, any market data included in this presentation involves assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. While BioNTech believes its own internal research is reliable, such research has not been verified by any independent source. In addition, BioNTech is the owner of various trademarks, trade names and service marks that may appear in this presentation. Certain other trademarks, trade names and service marks appearing in this presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this presentation may be referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

An abbreviation directory of defined terms can be found at the end of the presentation.


1
Progress Highlights
Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer
2
Oncology Execution
Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer
3
Financial Performance
Ramón Zapata, Chief Financial Officer
BIONTECH

1 Progress Highlights

Prof. Uğur Şahin, M.D.,
Co-Founder & Chief Executive Officer

BIONTECH


Oncology
Focus in
2026
1
Late-Stage Acceleration
Key late-stage data readouts expected for first wave of oncology assets
2
Combination Therapy Momentum
Novel-novel pumitamig[1] combination data readouts expected
3
Modalities to Disease Areas
Transition to a focused disease area specific approach
1. Partnered with Bristol Myers Squibb
5
BIONTECH

Building a Multi-Product Company by 2030

Targeting 17+ Late-Stage/Pivotal Trial Readouts Through 2030+ Informing Multiple Launch Opportunities

Tumor Type		Incidence[1]	Assets	Late-Stage/Pivotal Trials	Expected Data Readouts[2]
Lung	1L NSCLC	400K	Pumitamig[3]	ROSETTA Lung-02	2029
	Stage III unresectable NSCLC	65K	Pumitamig[3]	ROSETTA Lung-201	2030+
	1L NSCLC – PD-L1 ≥ 50%	60K	Pumitamig[3]	ROSETTA Lung-202	2030+
	2L+ sqNSCLC[1]	55K	Gotistobart[4]	PRESERVE-003	2026
	1L ES-SCLC	80k	Pumitamig[3]	ROSETTA Lung-01	2028
Breast	1L TNBC – all comers	20k	Pumitamig[3]	Phase 3 in China	2026
	1L TNBC – CPS < 10	15k	Pumitamig[3]	ROSETTA Breast-01	2029
	2L+ HR+ BC[1] – HER2-low	55k	Trastuzumab pamirtecan[5]	DYNASTY Breast-02	2026
Genitourinary	1L RCC	40k	Pumitamig[3]	ROSETTA RCC-208[7]	2030+
	1L CRPC	110k	BNT324/DB-1311[5]	BNT324-03	2029
Gastrointestinal	1L MSS-CRC	230k	Pumitamig[3]	ROSETTA CRC-203	2030+
	1L Gastric – HER2-neg, PD-L1+	40k	Pumitamig[3]	ROSETTA Gastric-204	2030+
	1L HCC	25k	Pumitamig[3]	ROSETTA HCC-206[7]	2030+
	Adj. CRC - ctDNA+	70k	Autogene cevumeran[6]	BNT122-01	2027
	Adj. PDAC	30k	Autogene cevumeran[6]	IMCODE003	2029
Gynecologic	2L+ Endometrial[1] – HER2-expressing	10k	Trastuzumab pamirtecan[5]	Single-arm Phase 2	2026
			Trastuzumab pamirtecan[5]	Fern-EC-01	2028
Additional Tumors	1L HNSCC – PD-L1 CPS ≥ 1, HPV16+	50k	BNT113	AHEAD-MERIT	2026

1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech's and its collaborators' product candidates, if approved. 2. Expected data readouts may be from interim or final analyses and are event-driven, and in some cases may not translate into commercial launches. Partnered with 3. Bristol Myers Squibb; 4. OncoC4; 5. DualityBio; 6. Genentech, a member of the Roche group; 7. These are Phase 1/2 trials. The anticipated pivotal trials evaluating pumitamig in these tumor types are expected to readout after 2030.

BIONTECH

2 Oncology Execution

Prof. Özlem Türeci, M.D.,
Co-Founder & Chief Medical Officer

BIONTECH

BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs



1. Partnered with Bristol Myers Squibb

BIONTECH

Broadening BioNTech's Coverage of Lung Cancer to Maximize Pipeline Potential



1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech's and its collaborators' product candidates, if approved; Partnered with: 2. Bristol Myers Squibb; 3. OncoC4; 4. DualityBio (BNT324/DB-1311, Sacituzumab **drozuntecan** (formerly BNT325-DB1305)); 5. MediLink (BNT326/YL202), 6. being conducted in China.

BIONTECH

Pumitamig Data Show Preliminary Antitumor Activity Irrespective of PD-L1 Expression in NSCLC

Phase 1/2 Trial in China Monotherapy Data at ELCC 2026 in Squamous and Non-squamous NSCLC across PD-L1 Expression

Median PFS

No. of patients at risk

Overall (NSQ & SQ)	30	22	22	17	7	6	4	3	3	3	2	1

Median OS



No. of patients at risk

Overall (NSQ & SQ)	30	29	27	26	13	10	7	6	6	6	4	4	0

Patient Population	Overall (n=30)	NSQ NSCLC		SQ NSCLC	
		PD-L1 1%–49% (n=9)	PD-L1 ≥50% (n=8)	PD-L1 1%–49% (n=6)	PD-L1 ≥50% (n=7)
cORR, % (95% CI)	**46.7** (28.3–65.7)	**44.4** (13.7–78.8)	**37.5** (8.5–75.5)	**33.3** (4.3–77.7)	**71.4** (29.0–96.3)
DCR, % (95% CI)	**96.7** (82.8–99.9)	**100** (66.4–100)	**100** (63.1–100)	**83.3** (35.9–99.6)	**100** (59.0–100)

Key Findings

- Encouraging antitumor activity in patients with previously untreated advanced NSCLC PD-L1 ≥1%, including those with squamous cell carcinoma
- Manageable safety & tolerability, with a low rate of treatment discontinuation
- Pumitamig monotherapy and in combination with chemotherapy for NSCLC is being further investigated in ongoing global studies

Zhang, et al. ELCC 2026 69P

Global Phase 2 pumitamig + chemotherapy data in 1L NSCLC expected at ASCO

BIONTECH

Broadening BioNTech's Coverage of Lung Cancer to Maximize Pipeline Potential



Next generation IO | Targeted therapy | mRNA immunotherapy | Registrational trials | Ph1/2 PoC trials

1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech's and its collaborators' product candidates, if approved; Partnered with: 2. Bristol Myers Squibb; 3. OncoC4; 4. DualityBio (BNT324/DB-1311, Sacituzumab **drozuntecan** (formerly BNT325-DB1305)); 5. MediLink (BNT326/YL202), 6. being conducted in China.

BIONTECH

Gotistobart Phase 3 Data Show Survival Benefit in CPI-Treated Squamous NSCLC

PRESERVE-003 trial stage 1 data at ELCC 2026: gotistobart[1] reduces risk of death by 54% compared with docetaxel

Overall Survival



	Gotistobart (n=45)	Docetaxel (n=42)
Median OS, months (95% CI)	**NE (9.33–NE)**	**9.95 (6.18–11.93)**
ORR, n (%)	**9 (20.0)**	**2 (4.8)**
Median PFS, months (95% CI)	**2.4 (2.1, 4.5)**	**2.6 (2.1, 3.9)**
12-month PFS rate, %	**25.2**	**0**
Median duration of follow-up, months (Q1, Q3)[3]	14.5 (13.0, 16.4)	15.2 (11.5, 16.0)

HR (95% CI): 0.46 (0.25–0.84)
Nominal *p*=0.0102[2]

Overall safety profile aligns with previously established safety profile

Kai He, et al. ELCC 2026 FPN 3O

Interim data from pivotal stage of Phase 3 trial expected in 2026

1. Partnered with OncoC4; 2. Not from formal hypothesis; 3.Calculated based on reversed Kaplan–Meier method with OS event as 0 (censored) and the last follow-up date or withdrawal date as event.

BIONTECH

BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs



1. Partnered with Bristol Myers Squibb

BIONTECH

Trastuzumab Pamirtecan: Encouraging Data in HER2-expressing EC

Data in Phase 1/2, Open-label, Dose-escalation and Expansion Study in HER2-expressing EC

Confirmed Objective Response Rate by HER2 IHC Score[1]



Efficacy Measures

	HER2-expressing (Central Testing)	
	Prior ICI (n=73)	All Patients (n=96)
Confirmed ORR,[3] % (95% CI)	49.3 (37.4, 61.3)	47.9 (37.6, 58.4)
Median DoR,[3] months (95% CI)	9.9 (7.0, NE)	11.1 (9.0, 18.3)
DCR,[3,4] % (95% CI)	79.5 (68.4, 88.0)	83.3 (74.4, 90.2)
Median PFS,[5] months (95% CI)	(n=74) 6.8 (5.4, 11.0)	(n=97) 8.1 (5.5, 11.8)

Key Findings

- 49.3% confirmed ORR by IRC in patients with prior ICI treatment and central testing for HER2-expression
- Responses were observed across all HER2 expression levels (IHC 1+, 2+ or 3+)
- Efficacy was consistent regardless of HER2 status by central or local testing
- Manageable safety profile

Pothuri, et al. SGO 2026

Phase 3 confirmatory study ongoing

1. By IRC in the modified FAS, which includes patients who received ≥1 dose of trastuzumab pamirtecan and had at least one measurable lesion as assessed by IRC at baseline according to RECIST v1.1; 2. IHC score was not available for one patient; patient tested positive by ISH; 3. By independent review committee in the modified FAS, which includes patients who received ≥1 dose of trastuzumab pamirtecan and had at least one measurable lesion as assessed by IRC at baseline according to RECIST v1.1; 4. Defined as complete response + partial response + stable disease for 5 weeks or longer; 5. Includes patients who received ≥1 dose of trastuzumab pamirtecan.

BIONTECH

Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios

Autogene cevumeran[1]

Adjuvant

CRC Phase 2	PDAC Phase 2
Monotherapy	+ Atezolizumab + mFOLFIRINOX
• Recruitment ongoing • Data presented from epi sub-study at **ASCO 2024** and from biomarker sub-study at **ESMO-GI 2024**	• Recruitment ongoing • Data from Phase 1 trial published: Rojas et al., **Nature 2023**; Sethna et al., **Nature 2025,** 6-year data update presented at **AACR 2026**
Phase 2 final analysis expected in 2027	**Primary Completion Date in 2031**

Individualized Immunotherapy – iNeST[1]

BNT113

1L

HPV16+ PD-L1 CPS ≥1 HNSCC Phase 2/3
+ Pembrolizumab
• Recruitment ongoing • Trial updated to Phase 2/3
Phase 3 interim analysis expected in 2026

BNT116

Multiple settings

NSCLC Phase 1 & 2
Mono & combo with IO & ADCs
• Recruitment completed in Phase 2 in 1L NSCLC[2] • Data presented at **SITC 2023, AACR 2024, SITC 2024** and **AACR 2026** • Data in frail patients presented at **AACR 2025** • Data in patients after CRT presented at **WCLC 2025**

Off-the-shelf Immunotherapy – FixVac

Partnered with: 1. Genentech, a member of the Roche Group; 2. In collaboration with Regeneron.

Catalyst-Rich Year Ahead with Multiple Expected 2026 Milestones

	Program	Trial Readout Phase	Indication
Late-Stage Trial Readouts	Trastuzumab pamirtecan[3]	Single arm Phase 2	2L+ HER2-expressing endometrial cancer
		Phase 3[5] interim analysis	Chemo naïve HR+ HER2-low breast cancer
	Gotistobart[2]	Phase 3[5] interim analysis	2L+ sqNSCLC
		Phase 2	2L+ mCRPC
	BNT113	Phase 3[5] interim analysis	1L HPV16+ PD-L1+ HNSCC
	Pumitamig[1]	Phase 3[5] in China interim analysis	1L TNBC
Early-Stage Pumitamig & ADC Trial Readouts	Pumitamig[1]	Phase 2	1L NSCLC
		Phase 2	1L ES-SCLC
		Phase 2 in China	1L HCC
		Phase 2 in China	1L MSS-CRC
	Pumitamig[1] + Trastuzumab pamirtecan[3]	Phase 1/2	Breast cancer
	Pumitamig[1] + BNT324/DB-1311[3]	Phase 2	Advanced solid tumors
		Phase 1/2	NSCLC/SCLC
	Pumitamig[1] + Sacituzumab drozuntecan[3]	Phase 2	TNBC
	Pumitamig[1] + BNT326/YL202[4]	Phase 1/2	NSCLC
	BNT324/DB-1311[3]	Phase 1/2	2L+ mCRPC
Phase 3 Trial Initiations	Pumitamig[1]	Phase 3[5]	1L MSS-CRC
			1L HER2- PD-L1+ gastric cancer
			1L NSCLC – PD-L1 ≥ 50%
			Stage III unresectable NSCLC
	BNT324/DB-1311[3]	Phase 3	1L mCRPC
BLA Submission	Trastuzumab pamirtecan[3]	-	2L+ HER2-expressing endometrial cancer
			Achieved

BioNTech and BMS are focused on maximizing and optimizing pumitamig's potential across tumor types. In response to the evolving treatment landscape, we are adapting previously announced development plans for pumitamig in HNSCC and no longer anticipate a Phase 3 HNSCC trial initiation in 2026.
Some data readouts may be event-driven and subject to change based on actual event accrual rates. Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. DualityBio; 4. MediLink; 5. Pivotal trial.

3 Financial Performance

Ramón Zapata,
Chief Financial Officer

First Quarter 2026 Financial Results

In € millions except per share data[1]	Q1 2026		Q1 2025	
	IFRS Results	Adjusted Results[2]	IFRS Results	Adjusted Results[2]
Revenues	118	118	183	183
Cost of sales	(71)	(71)	(84)	(84)
Research and development expenses	(557)	(527)	(526)	(526)
Sales, marketing, general and administrative expenses	(151)	(151)	(121)	(121)
Other operating result	(16)	(9)	13	(2)
Operating loss	**(677)**	**(640)**	**(534)**	**(549)**
Net loss	**(532)**	**(495)**	**(416)**	**(431)**
Diluted loss per share	(2.10)	(1.95)	(1.73)	(1.79)

Balance Sheet as of March 31, 2026 – Cash and cash equivalents plus security investments[3] €16.8 bn

1. All numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards,but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Cash and cash equivalents plus security investments as of March 31, 2026, reached €16,763.3 million, comprising €9,939.4 million in cash and cash equivalents, €4,696.9 million in current security investments disclosed as financial assets and €2,127.0 million in non-current security investments disclosed as financial assets.

BIONTECH

Reaffirming Full Year 2026 Financial Guidance[1]

In € millions	FY 2026 non-IFRS Guidance
Total Revenues	2,000 – 2,300
Adjusted R&D Expenses	2,200 – 2,500
Adjusted SG&A Expenses	700 – 800

Revenue Guidance Considerations

- Competitive market dynamics in the United States
- Begin managing transition away from multi-year contracts in Europe, and specifically in Germany where BioNTech recognizes direct sales for its COVID-19 vaccine
- Stable revenues from the collaboration with BMS, from a pandemic preparedness contract with the German government, and from the BioNTech Group service businesses
- No operationally-driven one-time revenue effect, such as from Pfizer opt-out from further development of shingles program

1. Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions ("M&A") transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov.

Focused Capital Allocation Strategy for Sustainable Value Creation

Focusing R&D Investments

Concentrate investments on advancing BioNTech's growing oncology pipeline toward commercialization, including pumitamig and ADC candidates

Planning Share Repurchase Program

Plan to initiate share repurchase program of up to $1.0 billion over the next twelve months

Manufacturing Footprint Consolidation

Enhance operational efficiency with expected cost savings to ramp up over time, reaching approximately €500 million in recurring annual savings upon full implementation of the measures in 2029[1]

1. Expected savings relative to BioNTech's 2025 cost base and CureVac's 2026 budget; do not reflect partially offsetting costs for CDMO use or transfer to other sites; and exclude exit costs, which will be recorded as incurred.

BioNTech Oncology Vision: Translating Science into Survival

Today

Advanced Strategy, Matured Pipeline and De-risked Development

Progress key programs into pivotal stage, leverage partnership with BMS, fortified balance sheet to fund our pipeline

2026-2029

Drive Oncology Execution at Scale and Speed

Advance combination therapy studies, accelerate pivotal trial execution, build indication-specific oncology portfolios and execute oncology launches

2030

Diversified Multi-Product Company

Build a diversified, multi-product global immunotherapy powerhouse addressing high unmet medical need of cancer patients worldwide


Thank you
BIONTECH

Appendix

Reconciliation of IFRS to Adjusted Results – Q1 2026 & 2025 Financial Results

In € millions except per share data[1]	Q1 2026 IFRS Results	Q1 2026 Non-IFRS Adjustments	Q1 2026 Adjusted Results[2]	Q1 2025 IFRS Results	Q1 2025 Non-IFRS Adjustments	Q1 2025 Adjusted Results[2]
Revenues	118	-	118	183	-	183
Cost of sales	(71)	-	(71)	(84)	-	(84)
Research and development expenses	(557)	30	(527)	(526)	-	(526)
Sales, marketing, general and administrative expenses	(151)	-	(151)	(121)	-	(121)
Other operating result	(16)	7	(9)	13	(15)	(2)
Operating loss	**(677)**	**37**	**(640)**	**(534)**	**(15)**	**(549)**
Net loss[3]	**(532)**	**37**	**(495)**	**(416)**	**(15)**	**(431)**
Basic and diluted loss per share	(2.10)		(1.95)	(1.73)		(1.79)

1. All Numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

BIONTECH

BioNTech's Oncology Pipeline



Partnered with: 1. Bristol Myers Squibb; 2. Genentech, a member of the Roche Group; 3. DualityBio; 4. OncoC4; 5. MediLink; 6. Genmab; 7. In collaboration with Regeneron; 8.Trial ongoing in China only; 9.Trial is currently being conducted by or on behalf of BioNTech. Bristol Myers Squibb holds co-exclusive rights to pumitamig.

BIONTECH

BioNTech's Infectious Diseases Pipeline

Phase 1	Phase 1/2	Phase 2	Commercial
BNT163[1] HSV	**BNT162 + BNT161**[2] COVID-19 – Influenza combination	**BNT166**[5] Mpox	**BNT162**[2,3] COVID-19
BNT351 HIV	**BNT164**[4] Tuberculosis		
	BNT165 Malaria		

Antibody mRNA

Partnered with: 1. University of Pennsylvania; 2. Pfizer; 3. Fosun Pharma; 4. Funded by the Gates Foundation; 5. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

BIONTECH

Abbreviation Directory

n L	*nth* line	ESMO	European Society for Medical Oncology	mRNA	Messenger ribonucleic acid
AACR	American Association for Cancer Research	FAS	APO-1 or CD95	MSS	Microsatellite stability
ADC	Antibody-drug conjugate	FixVac	Fixed Antigen Vaccine	NE	Not evaluable for response
adj.	Adjuvant	FY	Fiscal year	NEN	Neuroendocrine neoplasm
adv.	Advanced	G7 markets	Canada, France, Germany, Italy, Japan, GB, USA	NR	Not reached
ASCO	American Society of Clinical Oncology	GB	Great Britain	(sq) NSCLC	(squamous) Non-small cell lung cancer
BC	Breast cancer	GI	Gastrointestinal	(c)ORR	(confirmed) Objective response rate
BLA	Biologics License Applications	HCC	Hepatocellular carcinoma	OS	Overall survival
BMS	Bristol Myers Squibb	HER2 (or 3)	Human epidermal growth factor receptor 2 (or 3)	PD-(L)1	Programmed cell death protein (ligand) 1
CEPI	Coalition for Epidemic Preparedness Innovations	HIV	Human immunodeficiency virus	PDAC	Pancreatic ductal adenocarcinoma
		HNSCC	Head and neck squamous cell carcinoma	PFS	Progression-free survival
CDMO	Contract Development and Manufacturing Organization	HPV 16	Human papilloma virus 16	PoC	Proof of concept
		HR	Hormone receptor	PROC	Platinum-resistant ovarian cancer
CI	Confidence interval	HSV	Herpes simplex virus	R&D	Research and development
CPI	Checkpoint inhibitor	ICI	Immune checkpoint inhibitor	RCC	Renal cell carcinoma
CPS	Combined positive score	IFRS	International financial reporting standards	RECIST	Response Evaluation Criteria in Solid Tumors
CRC	Colorectal cancer	IHC	Immunohistochemistry	(ES)SCLC	(Extensive stage) small cell lung cancer
(m)CRPC	(met.) Castration resistant prostate cancer	IIT	Investigator initiated trial	SEC	Securities and Exchange Commission
CRT	Chemoradiation therapy	iNeST	Individualized NeoAntigen-Specific Therapy	SG&A	Selling, general and administrative expenses
ctDNA	Circulating tumor DNA	IO	Immuno-oncology	SITC	Society of Immunotherapy of Cancer
DCR	Disease control rate	IRC	Independent Review Committee	(n)sq	(non-)squamous
(m)DoR	(median) Duration of response	ISH	In-situ hybridyzation	TCE	T cell engager
EC	Endometrial cancer	M&A	Merger and acquisitions	TM	Trademark
EGFR(m)	(mutated) Epidermal growth factor receptor	met.	Metastatic	TNBC	Triple-negative breast cancer
ELCC	European Lung Cancer Congress	MPM	Malignant pleural mesothelioma	WCLC	World Conference of Lung Cancer
epi	Epidemiology	Mpox	Monkey pox		